A trial of abiraterone with either dactolisib or buparlisib for prostate cancer that is no longer responding to hormone therapy
Cancer type:
Status:
Phase:
This trial looked at abiraterone with either dactolisib or buparlisib for prostate cancer. It was for people whose cancer had continued to grow despite having hormone therapy.
The trial was open for people to join between 2012 and 2014. The team analysed the results in 2016. There are links to more information in the ‘Summary of results’ section below.
More about this trial
Doctors often treat prostate cancer with hormone therapy, including abiraterone. But sometimes the cancer continues to grow.
Researchers wanted to find out if either dactolisib (BEZ235) or buparlisib (BKM120) were useful alongside abiraterone for people in this situation.
Dactolisib and buparlisib are both types of targeted cancer treatments. They block the signals that cancer cells need to divide and grow. The men taking part had one of these treatments alongside abiraterone.
There were 2 parts to this trial.
In part 1, people had abiraterone and various doses of either dactolisib or buparlisib. This was to find the best dose to give.
In part 2, people were due to have abiraterone and a set dose of either dactolisib or buparlisib. But the trial was closed earlier than planned, before part 2 started.
The main aims of the trial were to find out:
- the best doses of dactolisib and buparlisib to give
- more about the side effects
- how well the treatments work
Summary of results
We aim to add a lay summary of results to all the trials on our database. Unfortunately we have not been able to include a summary for this one.
There is more information about the results in the link below.
Please note, the information we link to here is not in plain English. It has been written for healthcare professionals and researchers.
Phase Ib Dose Finding Study of Abiraterone Acetate Plus BEZ235 or BKM120 in Patients With Castration-resistant Prostate Cancer
Novartis Clinical Trial Results Database
Accessed March 2024
Phase Ib dose finding study of abiraterone acetate plus BEZ235 or BKM120 in patients with castration-resistant prostate cancer
EU Clinical Trials Register
Accessed March 2024
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Professor Johann de Bono
Supported by
Experimental Cancer Medicine Centre (ECMC)
Novartis
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
